KIRSCH ARTHUR S 4

What Happened

• Arthur S. Kirsch, a director of Evommune, bought 10,000 shares in open-market purchases on July 7, 2026. The reported weighted-average price was $13.30 per share, for an aggregate cost of approximately $133,000. This was a purchase (acquisition) rather than a sale.

Key Details

• Transaction date: 2026-07-07; filing date: 2026-07-08 (filed the next day — timely).
• Reported price: weighted average $13.30; actual trades ranged from $13.25 to $13.35 (per footnote).
• Total shares acquired: 10,000; total reported value: ~$133,000.
• Shares owned after transaction: not disclosed in the provided filing.
• Transaction code: P (purchase); securities held by a family trust (Kirsch is trustee) and Kirsch disclaims beneficial ownership except for his proportionate pecuniary interest (footnote).
• No 10b5-1 plan, option exercise, or award noted in this filing.

Context

• Open-market purchases by directors are often watched by investors as a direct personal investment signal, though filings alone don’t explain motivation. The shares here were placed into a family trust, which may affect how beneficial ownership is reported.